Zhao Yalei, Zhang Fen, Zhang Xiaoli, Li Zuhong, Li Qian, Ni Tianzhi, Wang Ruojing, Liu Liangru, He Yingli, Zhao Yingren
Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Regen Ther. 2023 Jul 21;24:256-266. doi: 10.1016/j.reth.2023.07.004. eCollection 2023 Dec.
The liver has an excellent ability to regenerate, and disrupted liver regeneration after various injuries leads to an unfavorable prognosis for patients. In this study, we sought to identify novel therapeutic hallmarks that are associated with yes-associated protein 1 (YAP1)-mediated hepatocyte proliferation during the process of liver regeneration.
Partial hepatectomy was conducted to induce liver regeneration in rats. Primary hepatocytes were isolated and cultured. Hepatocyte proliferation was assessed using immunohistochemistry staining, and expression of YAP1 was detected. RNA sequencing and bioinformatics analysis were used to search for potential regulators of YAP1. The association between ubiquitin-specific peptidase 1 (USP1) and YAP1 was validated using and experiments.
YAP1 was significantly elevated in regenerative hepatocytes, especially in the nucleus. Knockdown of YAP1 using small interfering RNA or pharmacological inhibition using verteporfin significantly attenuated the proliferation of hepatocytes. The bioinformatics analysis results revealed that USP1 was associated with YAP1-mediated hepatocyte proliferation during liver regeneration. ML-323, a specific inhibitor of USP1-USP1 associated factor 1 (UAF1), significantly decreased the expression of YAP1, Cyclin D1, and proliferating cell nuclear antigen, while these decreased expressions could be rescued by YAP1 overexpression. Furthermore, ML-323 treatment significantly inhibited liver regeneration following partial hepatectomy.
In conclusion, we identified USP1 as a novel biomarker that is associated with YAP1-mediated hepatocyte proliferation in liver regeneration. Pharmacological inhibition of USP1 by ML-323 substantially impairs hepatocyte proliferation during liver regeneration.
肝脏具有出色的再生能力,各种损伤后肝脏再生受干扰会导致患者预后不良。在本研究中,我们试图确定在肝脏再生过程中与Yes相关蛋白1(YAP1)介导的肝细胞增殖相关的新治疗靶点。
对大鼠进行部分肝切除术以诱导肝脏再生。分离并培养原代肝细胞。使用免疫组织化学染色评估肝细胞增殖,并检测YAP1的表达。采用RNA测序和生物信息学分析来寻找YAP1的潜在调节因子。使用 和 实验验证泛素特异性肽酶1(USP1)与YAP1之间的关联。
YAP1在再生肝细胞中显著升高,尤其是在细胞核中。使用小干扰RNA敲低YAP1或使用维替泊芬进行药理抑制可显著减弱肝细胞的增殖。生物信息学分析结果显示,在肝脏再生过程中USP1与YAP1介导的肝细胞增殖相关。ML-323是USP1-USP1相关因子1(UAF1)的特异性抑制剂,可显著降低YAP1、细胞周期蛋白D1和增殖细胞核抗原的表达,而这些降低的表达可通过YAP1过表达得到挽救。此外,ML-323处理显著抑制部分肝切除术后的肝脏再生。
总之,我们确定USP1是一种与肝脏再生中YAP1介导的肝细胞增殖相关的新生物标志物。ML-323对USP1的药理抑制作用在肝脏再生过程中显著损害肝细胞增殖。